5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO

Achieving 15 per cent year-on-year growth, with nearly four biosimilars with $200 million in revenue, is a big feat, says Tambe

Biocon Biologics (BBL) reported robust growth in 2024-25 (FY25), driven by rising biosimilar market share in the US and emerging markets (EMs). Its Managing Director and Chief Executive Officer Shreehas P Tambe, in conversation with Anjali Singh and Aneeka Chatterjee, outlines the company’s product pipeline, insulin strategy, glucagon-like peptide-1 (GLP-1) plans, and efforts to strengthen global presence. Edited excerpts:

 

What were the key drivers for BBL’s growth in the fourth quarter of FY25?

 

Achieving 15 per cent year-on-year revenue growth, with nearly four biosimilars generating $200 million in revenue, is a huge feat. It reflects strong customer confidence in our